Updated clinical practice guidelines recommend the long-term use of low-molecular-weight
heparins or direct oral anticoagulants as the preferred option for the treatment of cancer …

Introduction: We update the knowledge, since the last review in 2017, about drug–drug
interactions (DDI) of non-vitamin-K-antagonist oral anticoagulants (NOAC) in patients≥ 75 …

Objective The study of ABCB1 and CYP3A4/3A5 gene polymorphism genes is promising in
terms of their influence on prothrombin time variability, the residual equilibrium …

As a novel acid-suppressing drug, vonoprazan shows the potential to replace traditional
proton-pump inhibitors. With its widespread use, some adverse effects that require further …

The combination of Salvia miltiorrhiza (Danshen) and rivaroxaban is a promising treatment
option in clinical practice in China, but the herb–drug interaction between Danshen and …

Introduction In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the
vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial …

Background Anticoagulants and antiplatelet drugs are risk factors for gross hematuria (GH).
Moreover, co-medication and drug-drug interactions (DDIs) may influence GH and its clinical …

Introduction Current guidelines suggest preoperative direct oral anticoagulant levels of< 30-
50ng/ml. However, there is limited evidence to guide this expert consensus. Reviewing …

Лекарственно-индуцированная фибрилляция/трепетание предсердий (ЛИФП/ТП)
представляет собой серьезное и потенциально угрожающее жизни осложнение …

На примере технологий персонализации фармакотерапии на основе биомаркеров
процессов всасывания, распределения, метаболизма и выведения лекарственных …